APA

Stathis A., Flinn I. W., Madan S., Maddocks K., Freedman A., Weitman S., Zucca E., Munteanu M. C. & Lia Palomba M. (20190603). Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. : Investigational new drugs.

Chicago

Stathis Anastasios, Flinn Ian W, Madan Sumit, Maddocks Kami, Freedman Arnold, Weitman Steven, Zucca Emanuele, Munteanu Mihaela C and Lia Palomba M. 20190603. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. : Investigational new drugs.

Harvard

Stathis A., Flinn I. W., Madan S., Maddocks K., Freedman A., Weitman S., Zucca E., Munteanu M. C. and Lia Palomba M. (20190603). Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. : Investigational new drugs.

MLA

Stathis Anastasios, Flinn Ian W, Madan Sumit, Maddocks Kami, Freedman Arnold, Weitman Steven, Zucca Emanuele, Munteanu Mihaela C and Lia Palomba M. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. : Investigational new drugs. 20190603.